At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Obstetric Liposomal Bupivacaine Via Surgical Transversus Abdominis Plane Block for Post Cesarean Pain Control: a Single-blind Pilot Randomized Controlled Trial
In Brief
A Phase 4 clinical trial evaluating Liposomal bupivacaine, Bupivacaine Hydrochloride, and 1 other intervention for Cesarean Section Complications and 2 related conditions. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This study seeks to identify whether the addition of liposomal bupivacaine to regular bupivacaine and saline administered via surgical transversus abdominis plane (TAP) block will reduce the cumulative opioid dose in the first 48 hours after cesarean. 60 women scheduled for cesarean at Unity-Point Health Meriter Hospital in Madison, Wisconsin will be enrolled and can be expect to be on study for up to 6 weeks post-partum.
Study Details
Timeline
Interventions
20 mL prior to closing fascia, the active drug (bupivacaine) is encapsulated in a liposomal platform and released slowly over the course of days with an approximate 72 hour duration.
30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic
post-surgical saline